fbpx

Nyheder

Lundbeckfonden Ventures nyheder

First-in-Class Anabolic Catabolic Transforming Agent Shown to Reverse Cachexia's Effects in Stage III and IV Lung and Colorectal Cancer Patients PsiOxus Therapeutics, Ltd. (PsiOxus) today announced top line positive data from a Phase II clinical trial of MT-102 in cancer-related cachexia. The primary endpoint has been met in the recently completed Phase II multinational, randomized,...
  Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem in cancer patients receiving emetogenic chemotherapy despite the availability of a range of anti-emetic medications....
  BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that a comprehensive review article summarizing available published and presented data for composite products containing calcium sulphate and hydroxyapatite, extensively refers to preclinical studies and clinical applications published on CERAMENTT’BONE VOID...
Study presented at the Combined Orthopaedic Research Society Meeting in Venice, Italy   BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a five-year follow-up study on patients treated with CERAMENTT’BONE VOID FILLER, as presented at the Combined Orthopaedic Research...
  . Leading US centers in food allergy will be involved in an NIH-funded CoFAR study, coordinated by Dr. Sampson and Dr. Jones in collaboration with DBV’ team. CoFAR6 study will help to better characterize the mechanisms of action of epicutaneous immunotherapy DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new approach...
This Proof of concept study aims to capitalize on DBV’s safe and non-invasive technology and Inserm’s unique expertise to address refractory Hemophilia A, a severe orphan disease with no cost-effective and convenient treatment today available to patients DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies,...
  Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that it has appointed Michael Narachi as Chairman of the Board of Directors. Michael currently serves as President and Chief Executive Officer of Orexigen Therapeutics, Inc. Michael has 29 years...
Stallergenes to exercise option to develop and commercialize a birch allergy new product DBV eligible for milestone payments and royalties on Stallergenes’ net sale Stallergenes acquires an equity position in DBV Stallergenes S.A. (Euronext Paris: GENP), worldwide leader in allergen immunotherapy, and DBV Technologies (Euronext Paris: DBV), creator of Viaskin® for the treatment of allergies,...
  The Independant Data and Safety Monitoring Board (DSMB) recommends VIPES continuation without modifications DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today its topline financial results for first nine months 2013 and provided a clinical update on VIPES (Viaskin Peanut’s Efficacy and Safety),...
1 46 47 48 49 50 59

Lundbeckfonden Ventures

Nyheder

BONESUPPORT HOLDING AB presents health economic evidence
19. september 2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
17. september 2019
Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
17. september 2019